Join

Compare · CSII vs DXCM

CSII vs DXCM

Side-by-side comparison of Cardiovascular Systems Inc. (CSII) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CSII and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • DXCM is the larger of the two at $26.59B, about 38.1x CSII ($698.7M).
  • DXCM has hit the wire 18 times in the past 4 weeks while CSII has been quiet.
  • DXCM has more recent analyst coverage (25 ratings vs 8 for CSII).
MetricCSIIDXCM
Company
Cardiovascular Systems Inc.
DexCom Inc.
Price
$19.99+0.05%
$68.89-0.24%
Market cap
$698.7M
$26.59B
1M return
-
-4.14%
1Y return
-
-21.33%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NASDAQ
IPO
1981
2005
News (4w)
0
18
Recent ratings
8
25
CSII

Cardiovascular Systems Inc.

Cardiovascular Systems, Inc., a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.

DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Latest CSII

Latest DXCM